Yesterday, on June 3, 2020, the first part of the BIC Webinar series was successfully held! 78 participants from all over the world attended the first BIC webinar on “How to Commercialise your Biomarker Discovery”.
The webinar focused on the biomarker commercialization process and the biomarker commercialization guide.
The BIC guide covers technical, clinical, commercial and regulatory aspects, and it is designed to support, step-by-step, both academic researchers and SMEs when developing a Biomarker based invention into a commercial product.
Other tools created during the project will be:
-> Best Practices Handbook based on experiences from TTOs in the field
-> Review tool for TTOs
-> Guide for Regulatory Process
- “BIC Guide: a set of tools for supporting Biomarker Commercialization”
Valerie Daussin, Project Leader for the BIC consortium, University Hospital of Aalborg
Valerie Daussin Laurent is a business developer at Aalborg University Hospital in Denmark. She has 20 years of experience within innovation, patenting and technology transfer. With a background as a legal adviser in Intellectual Property Rights, she assists researchers from the hospital from discovery to the industrial phase. The support includes patenting, fundraising as well as business development and negotiation with the partners. For the last 2 years, she has been project leader for the BIC consortium.
- “SME experience with BIC Guide”
Huram Konjen, CEO of Dianox
Huram Konjen is the CEO of Dianox, a biotechnology company developing diagnostics for infectious diseases. Huram has a master’s degree in Digital Innovation and Management and previously worked at Deloitte as a Management Consultant, where he facilitated innovation labs for companies wanting to develop sustainable products.
Moderator: Teppo Laaksonen.
Teppo Laaksonen is a Network Manager at HealthTurku cluster, Turku Science Park Ltd. He has 30 years of experience in the diagnostic industry, in large companies and SMEs. His responsibilities included quality systems, regulatory affairs of medical devices, SME funding, development of platform technology, international marketing, sales and cooperation, and has know-how related to IVD markets and trends. In regard to biomarker commercialization he has knowledge on biomarker registration, quality assurance policy, product development, and upscaling of production.
*BIC is an Interreg program in the Baltic Sea Region that develops support tools for researchers, technology transfer offices and SMEs for better and more successful commercialisation of biomarkers inventions. The current results of the BIC project is a set of tools that conduct and guide the user through the discovery and innovative process, integrating not only technical and clinical task but also commercial and regulatory considerations.For more information on biomarker commercialization visit the project’s website: biomarker.nu